Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: Now you see them, now you don't

Journal of Neurology

Volumn 261, Issue 4, 2014, Pages 809-816

  Leppert, Ilana R ^a   Narayanan, S ^a   Araujo D ^a   Giacomini, P S ^a   Lapierre, Y ^a   Arnold, D L ^a   Pike, G B ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

DCE MRI; Lesion enhancement; Limit of detection; Permeability; Therapy; Time course

Indexed keywords

GADOBUTROL; GADOLINIUM; CONTRAST MEDIUM;

ARTICLE; BLOOD BRAIN BARRIER; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; ADOLESCENT; ADULT; ALGORITHM; DIAGNOSTIC USE; FEMALE; IMAGE PROCESSING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES; SIGNAL NOISE RATIO; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SIGNAL-TO-NOISE RATIO; YOUNG ADULT;

EID: 84898883750     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7284-0     Document Type: Article

References (33)

1. Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, Frank JA, Kappos L, Li D, Menzler S, Miller DH, Petkau J, Wolinsky J, for the Sylvia Lawry Centre for MSR (2005) Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65:1447-1454 (Pubitemid 41552778)
2. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD (2009) Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72:1976-1983
3. Cotton F, Weiner H, Jolesz F, Guttmann C (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60:640-646 (Pubitemid 36246083)
4. Deoni SC, Rutt BK, Peters TM (2003) Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 49:515-526 (Pubitemid 36262820)
5. Dhib-Jalbut S (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3-S9
6. Durelli L, Clerico M (2005) Comparison of immunomodulatory treatments for multiple sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 12:915
7. Erskine MK, Cook LL, Riddle KE, Mitchell JR, Karlik SJ (2005) Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci 32:205-212 (Pubitemid 40839963)
8. Filippi M, Mastronardo G, Bastianello S, Rocca MA, Rovaris M, Gasperini C, Pozzilli C, Comi G (1998) A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. J Neurol Sci 159:94-101 (Pubitemid 28365890)
9. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, Prandini F, Horsfield MA, Martinelli V, Bastianello S, Kühne I, Pozzilli C, Comi G (1998) A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 121:2011-2020 (Pubitemid 28454367)
10. Footit C, Cron GO, Nguyen TV, Cameron I, Schweitzer ME, Sinclair J, Woulfe J, Hogan MJ, Nguyen TB (2011) Optimizing perfusion imaging of brain tumors: Validation of venous output function used as a surrogate AIF. In: 19th Proceedings of the international society for magnetic resonance in medicine. Abstract #2038
11. Francis G (2004) Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 251(Suppl):5
12. Gay D, Esiri M (1991) Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain J Neurol 114(Pt 1B):557-572
13. Giovannoni G, Silver NC, Good CD, Miller DH, Thompson EJ (2000) Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis. Eur Neurol 44:222-228
14. Ingrisch M, Sourbron S, Morhard D, Ertl-Wagner B, Kümpfel T, Hohlfeld R, Reiser M, Glaser C (2012) Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3 T. Invest Radiol 47:252-258
15. Jelescu IO, Leppert IR, Narayanan S, Araújo D, Arnold DL, Pike GB (2011) Dual-temporal resolution dynamic contrast-enhanced MRI protocol for blood-brain barrier permeability measurement in enhancing multiple sclerosis lesions. J Magn Reson Imaging 33:1291-1300
16. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI meta-analysis group. Lancet 353:964-969 (Pubitemid 29132605)
17. Lavini C, Verhoeff J (2010) Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging
18. Livshits I, Hussein S, Kennedy C, Weinstock-Guttman B, Hojnacki D, Zivadinov R (2012) Comparison of a 1.5 T standard vs. 3 T optimized protocols in multiple sclerosis patients. Minerva Med 103:97-102
19. Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D, Schwid S, Stubinski B, Uitdehaag B (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903-914
20. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T (2009) 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889-897
21. Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS (2008) Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 14:770-778
22. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715-724 (Pubitemid 41546838)
23. Sicotte NL, Voskuhl RR, Bouvier S, Klutch R, Cohen MS, Mazziotta JC (2003) Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 38:423-427 (Pubitemid 36791336)
24. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120:1149-1161 (Pubitemid 27285734)
25. Silver NC, Good CD, Sormani MP, MacManus DG, Thompson AJ, Filippi M, Miller DH (2001) A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 248:215-224 (Pubitemid 32245498)
26. Sormani M, Bonzano L, Roccatagliata L, Cutter G, Mancardi G, Bruzzi P (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65:268-275
27. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N (2011) Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 77:1684-1690
28. Tofts PS (1996) Optimal detection of blood-brain barrier defects with Gd-DTPA MRI - the influences of delayed imaging and optimised repetition time. Magn Reson Imaging 14:373-380 (Pubitemid 26195072)
29. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
30. Wattjes M, Lutterbey G, Harzheim M, Gieseke J, Träber F, Klotz L, Klockgether T, Schild H (2006) Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 16:2067-2073 (Pubitemid 44193191)
31. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ (1994) Triple-dose versus single dose gadoteridol in multiple sclerosis patients. J Neuroimaging 4:141-145 (Pubitemid 24232362)
32. Wu Y-Y, Wu C-H, Chiang C-M, Chen C-C, Chai J-W (2012) Consistency of permeability measurement using arterial input function and venous output function in DCE-MRI for metastatic brain tumors. In: 20th Proceedings of the international society for magnetic resonance in medicine. Abstract #3508
33. Yong W (2002) Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59:802-808